Potential therapy of umbilical cord mesenchymal stem cells (UC-MSC) in renal fibrosis

Evi Lusiana*    -  Department of Pharmacology, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia, Indonesia
Legiran Legiran  -  Department of Biomedicine, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia

(*) Corresponding Author
DOI: 10.30659/sainsmed.v14i1.22458

Renal fibrosis (RF) is a severe kidney pathology defined by myofibroblast anomalies that create extracellular material on the interstitial and glomerular surfaces. The current therapy for treating renal disease has not achieved excellent results. A new theory about applying umbilical cord mesenchymal stem cells (UC-MSC) to treat renal fibrosis and other fibrosis-affected organs has been developed. This review aims to elucidate the role of UC-MSC in the therapy of renal fibrosis and summarize the numerous biological mechanisms involved. A search was undertaken using PubMed and Google Scholar from 2003 to 2021 to gather information regarding the Potential therapy with UC-MSC in renal fibrosis. Multiple studies on rat models of renal fibrosis have demonstrated a considerable improvement in fibrotic kidneys following UC-MSC treatment. It can transfer functional proteins and genetic information to recipient cells that suppress the fibrosis process. UC-MSC is considered a superior approach to MSC for therapeutic purposes due to its straightforward collection, minimum immunogenicity, and solid paracrine potency. The UC-MSC cellular treatment for renal impairment is a feasible option in the future.

Keywords: chronic kidney disease; acute kidney injury; unilateral ureteral obstruction.

  1. Cho, M. H. (2010). Renal fibrosis. Korean Journal of Pediatrics, 53(7): 735–740. doi: 10.3345/kjp.2010.53.7.735.
  2. Couser, W.G., Remuzzi, G., Mendis, S., and Tonelli, M. (2011). The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney International, 80(12): 1258–70. doi: 10.1038/ki.2011.368.
  3. Devine, S.M., Cobbs, C., Jennings, M., Bartholomew, A., and Hoffman, R. (2003). Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood, 101(8): 2999–3001. doi: 10.1182/blood-2002-06-1830.
  4. Du, T., Zou, X., Cheng, J., Wu, S., Zhong, L., Ju, G., Zhu, J., Liu, G., Zhu, Y., and Xia, S. (2013). Human Wharton’s jelly-derived mesenchymal stromal cells reduce renal fibrosis through induction of native and foreign hepatocyte growth factor synthesis in injured tubular epithelial cells. Stem Cell Research & Therapy, 4(59): 1-13. doi 10.1186/scrt215.
  5. Eddy, A. A. (2014). Overview of the cellular and molecular basis of kidney fibrosis. Kidney International Supplements, 4(1): 2–8. doi: 10.1038/kisup.2014.2.
  6. Fan, Y.P., Hsia, C.C., Tseng, K.W., Liao, C.K., Fu, T.W., Ko, T.L., Chiu, M.M., Shih, Y.H., Huang, P.Y., Chiang, Y.C, Yang, C.C., and Fu, Y.S. (2016). The therapeutic potential of human umbilical mesenchymal stem cells from Wharton’s Jelly in the treatment of rat peritoneal dialysis-induced fibrosis. Stem Cells Translational Medicine, 5(2): 235–247. doi: 10.5966/SCTM.2015-0001.
  7. François, H. and Chatziantoniou, C. (2018). Renal fibrosis: Recent translational aspects., Matrix Biology, Volume 68–69: 318–332. doi: 10.1016/j.matbio.2017.12.013.

Open Access Copyright (c) 2023 Sains Medika
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Sains Medika: Jurnal Kedokteran dan Kesehatan
is published by Faculty of Medicine Universitas Islam Sultan Agung, Indonesia in association with FOKI (FORUM KEDOKTERAN ISLAM INDONESIA).

Contact: Jl. Raya Kaligawe Km.4, PO BOX 1054/SM Semarang 50112, Indonesia
Phone: +62 8122-9933-369
Website: https://fkunissula.ac.id
Email: sainsmedika@unissula.ac.id

ISSN: 2339-093X (Online) | 2085-1545 (Print)
DOI : 10.30659/sainsmed

This work is licensed under a Creative Commons Attribution 4.0 International License

Get a feed by atom here, RRS2 here and OAI Links here

apps